Steadybase.

Sionna Therapeutics, Inc.

Website Investor relations LinkedIn Latest 10-K
  • SION · Nasdaq
  • Pharmaceutical Preparations
  • Waltham, MA
  • 59 employees
  • CIK 0002036042

Updated from SEC filings through

Top things to know

Executives

What leadership is saying

“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination”

Mike Cloonan, President and Chief Executive Officer of Sionna
Earnings press release (8-K Ex. 99.1), filed November 10, 2026

Sionna Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Waltham, MA. It trades as SION on Nasdaq. It reported about 59 employees. Michael Cloonan is President & CEO.

Five-year financials

MetricFY2025FY2024
Revenue Not on file Not on file
Operating income -$89.0M
10-K, 2026-03-02
-$70.6M
10-K, 2026-03-02
SG&A $28.7M
10-K, 2026-03-02
$13.3M
10-K, 2026-03-02
Net income -$75.3M
10-K, 2026-03-02
-$61.7M
10-K, 2026-03-02

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Michael Cloonan
President and Chief Executive Officer, Sionna Therapeutics
President & CEO Form 4, September 18, 2026
Elena Ridloff CFO and CBO Form 4, September 18, 2026
Caroline Stark Beer Chief Business Officer Form 4, January 6, 2026
Charlotte McKee CMO and Head of R&D Form 4, September 18, 2026
Jennifer Fitzpatrick CLO and Head of Program Mgmt. Form 4, September 18, 2026

What Sionna Therapeutics, Inc. does

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 45.2 million (as of October 30, 2026) 10-Q, November 10, 2026
Public float $342M (as of June 30, 2025) 10-K, March 2, 2026
Reportable segments 1 (period ending December 31, 2025) 10-K, March 2, 2026
Latest proxy statement Meeting June 17, 2026 (filed April 27, 2026) DEF 14A, April 27, 2026
Auditor Deloitte & Touche LLP (Boston, Massachusetts) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
September 17, 2026 Rajeev M. Shah
Director
Sale 3,448,811 $21.8M Form 4, September 21, 2026
September 17, 2026 Capital Nexus Fund L.P. RA
Director
Sale 3,448,811 $21.8M Form 4, September 21, 2026
September 17, 2026 Capital Nexus Fund L.P. RA III
Director
Sale 3,448,811 $21.8M Form 4, September 21, 2026
September 17, 2026 Capital Healthcare Fund LP RA
Director
Sale 3,448,811 $21.8M Form 4, September 21, 2026
September 17, 2026 Capital Management L.P. Ra
Director
Sale 3,448,811 $21.8M Form 4, September 21, 2026
September 17, 2026 Peter Kolchinsky
Director
Sale 3,448,811 $21.8M Form 4, September 21, 2026
July 7, 2026 Peter A. Thompson
Director
Sale 85,918 $3.9M Form 4, July 9, 2026
July 7, 2026 Advisors Llc Orbimed
Director
Sale 85,918 $3.9M Form 4, July 9, 2026

Recent 8-K events

Frequently asked questions about Sionna Therapeutics, Inc.

What does Sionna Therapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function."
How many employees does Sionna Therapeutics, Inc. have?
About 59 as of December 31, 2025, as stated in its annual report.
Who is the CEO of Sionna Therapeutics, Inc.?
Michael Cloonan, President & CEO, as named in a 4 filed September 18, 2026.
Who is the CFO of Sionna Therapeutics, Inc.?
Elena Ridloff, CFO and CBO, as named in a 4 filed September 18, 2026.
Where is Sionna Therapeutics, Inc. headquartered?
Waltham, MA.
What is Sionna Therapeutics, Inc.'s stock ticker?
SION on Nasdaq.
What industry is Sionna Therapeutics, Inc. in?
Pharmaceutical Preparations, SIC code 2834.
What is Sionna Therapeutics, Inc.'s website?
sionnatx.com. Investor relations: https://investors.sionnatx.com/.
When does Sionna Therapeutics, Inc. report earnings next?
February 4, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Sionna Therapeutics, Inc. a public company?
Yes. Sionna Therapeutics, Inc. files with the SEC under CIK 0002036042 and trades as SION.
Who audits Sionna Therapeutics, Inc.?
Deloitte & Touche LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
How many shares of Sionna Therapeutics, Inc. are outstanding?
45.2 million shares as of October 30, 2026, from its 10-Q filed November 10, 2026.
What is Sionna Therapeutics, Inc.'s public float?
$342M as of June 30, 2025, as reported on the cover of its 10-K filed March 2, 2026.
How many business segments does Sionna Therapeutics, Inc. report?
1 reportable segment for the period ending December 31, 2025, from its 10-K filed March 2, 2026.
When is Sionna Therapeutics, Inc.'s annual shareholder meeting?
June 17, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
Have Sionna Therapeutics, Inc. insiders traded stock recently?
Since November 21, 2025, officers and directors reported 45 open-market sales worth about $305M and 0 purchases on Forms 4 and 5. The most recent: Rajeev M. Shah (Director) sold 3,448,811 shares on September 17, 2026.